CompanyCLYMNasdaqWellesley Hills, MA

Climb Bio, Inc.

Climb Bio develops monoclonal antibodies for immune-mediated diseases.

SEC EDGAR ClinicalTrials.gov ir.climbbio.com

DEF 14ASep 28Latest SEC filing

Sep 3Latest story

September 2026

Climb Bio reports Phase 1 data for anti-APRIL antibody CLYM116 in IgA nephropathy program

Sep 3Clinical readoutClimb Bio, Inc.

August 2026

Climb Bio reports Q2 2026 results, sets CLYM116 R&D event and Phase 2 start

Aug 6Quarterly updateClimb Bio, Inc.

July 2026

Climb Bio board sees director resignation, adds Breanna O'Reilly

Jul 1PeopleClimb Bio, Inc.